Back to search
FDAFDA · Food and drugs·Recall number D-0052-2023

PROSTAGLANDIN E1 INJECTION SOLUTION 500MCG/ML SOLUTION, 1 ML vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402

Published November 9, 2022 · Recall initiated: October 7, 2022

Summary

FDA records drug Class II recall D-0052-2023, published November 9, 2022 and initiated October 7, 2022. Recalling firm: Pharmacy Plus, Inc. dba Vital Care Compounder; Status: Ongoing; Reported quantity: 50 vials; Lot: Lots: 59993 BUD: 10/18/2022; 60932 BUD: 11/09/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

What to do

Voluntary: Firm initiated · Telephone

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pharmacy Plus, Inc. dba Vital Care Compounder
Distributor
AL, LA, MS, and TN
Lot
Lots: 59993 BUD: 10/18/2022; 60932 BUD: 11/09/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was PROSTAGLANDIN E1 INJECTION SOLUTION 500MCG/ML SOLUTION, 1 ML vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402 recalled?

Yes. FDA published recall D-0052-2023 on November 9, 2022. Reported hazard: Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

What should I do if I have this product?

Voluntary: Firm initiated · Telephone